You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Vitamin E and selenium do not decrease prostate cancer incidence: vitamin E may actually increase it
  1. Samay Jain,
  2. Ravi Munver,
  3. Ihor S Sawczuk
  1. Department of Urology, Hackensack University Medical Center, Hackensack, New Jersey, USA
  1. Correspondence to Samay Jain
    Department of Urology, Hackensack University Medical Center, 360 Essex St Suite 403, Hackensack, NJ 07601, USA; samayjain{at}humed.com

https://doi.org/10.1136/ebmed-2011-100472

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Klein EA, Thompson IM Jr., Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549–56.OpenUrlCrossRefPubMedWeb of Science

    Context

    The Selenium and vitamin E Cancer Prevention Trial (SELECT)1 trial was designed to determine whether oral selenium, vitamin E or both could affect a man's risk of being diagnosed with prostate cancer. Interim analysis of the trial had shown no benefit to supplementation with selenium and vitamin E on the incidence of prostate cancer. The study by Klein et al presents updated results from a longer follow-up period.

    Methods

    The effect of selenium and vitamin E on the risk of prostate cancer was studied in 35 151 study subjects. Men were eligible if they were at least 55 years old (50 years old for African–American men), had a normal digital rectal exam …

    View Full Text

    Footnotes

    • Competing interests None.